Dipeptidyl-peptidase IV (DPP-IV) inhibitor delays tolerance to anxiolytic effect of ethanol and withdrawal-induced anxiety in rats

Metabolic Brain Disease

Volumn 30, Issue 3, 2015, Pages 659-667

  Sharma, Ajaykumar N ^a,b   Pise, Ashish ^a   Sharma, Jay N ^c   Shukla, Praveen ^d  

^a STES's Smt Kashibai Navale College of Pharmacy   (India)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcohol dependence; Anxiety; DPP IV; Sitagliptin; Tolerance

Indexed keywords

ALCOHOL; ANXIOLYTIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ANIMAL; ANXIETY; COMPLICATION; DRUG TOLERANCE; ETIOLOGY; MALE; PHYSIOLOGY; PSYCHOLOGY; RAT; SUBSTANCE WITHDRAWAL SYNDROME; WISTAR RAT;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG TOLERANCE; ETHANOL; MALE; RATS; RATS, WISTAR; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84939889518     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-014-9603-7     Document Type: Article

References (45)

1. Kushner MG, Thuras P, Abrams K, Brekke M, Stritar L (2001) Anxiety mediates the association between anxiety sensitivity and coping-related drinking motives in alcoholism treatment patients. Addict Behav 26:869–885
2. Kushner MG, Abrams K, Borchardt C (2000) The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings. Clin Psychol Rev 20:149–171
3. Sharma AN, Chopde CT, Hirani K, Kokare DM, Ugale RR (2007) Chronic progesterone treatment augments while dehydroepiandrosterone sulphate prevents tolerance to ethanol anxiolysis and withdrawal anxiety in rats. Eur J Pharmacol 567:211–222. doi:10.1016/j.ejphar.2007.04.025
4. Samson HH, Harris RA (1992) Neurobiology of alcohol abuse. Trends Pharmacol Sci 13:206–211
5. Roelofs SM (1985) Hyperventilation, anxiety, craving for alcohol: a subacute alcohol withdrawal syndrome. Alcohol 2:501–505
6. Sinclair JD, Lindros KO (1981) Suppression of alcohol drinking with brain aldehyde dehydrogenase inhibition. Pharmacol Biochem Behav 14:377–383
7. Krystal JH, Petrakis IL, Mason G, Trevisan L, D’Souza DC (2003) N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol Ther 99:79–94
8. Mann K, Kiefer F, Spanagel R, Littleton J (2008) Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 32:1105–1110. doi:10.1111/j.1530-0277.2008.00690.x
9. Addolorato G, Leggio L, Cardone S, Ferrulli A, Gasbarrini G (2009) Role of the GABA (B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives. Alcohol 43:559–563. doi:10.1016/j.alcohol.2009.09.031
10. Lejoyeux M, Solomon J, Ades J (1998) Benzodiazepine treatment for alcohol-dependent patients. Alcohol 33:563–575
11. Mukherjee PK (1983) A comparison of the efficacy and tolerability of clobazam and chlordiazepoxide in the treatment of acute withdrawal from alcohol in patients with primary alcoholism. J Int Med Res 11:205–211
12. Nutt D, Adinoff B, Linnoila M (1989) Benzodiazepines in the treatment of alcoholism. Recent Dev Alcohol 7:283–313
13. Jarosz J, Miernik K, Wachal M, Walczak J, Krumpl G (2013) Naltrexone (50 mg) plus psychotherapy in alcohol-dependent patients: a meta-analysis of randomized controlled trials. Am J Drug Alcohol Abuse 39:144–160. doi:10.3109/00952990.2013.796961
14. Soyka M (2014) Nalmefene for the treatment of alcohol dependence: a current update. Int J Neuropsychopharmacol 17:675–684. doi:10.1017/S1461145713001284
15. Zindel LR, Kranzler HR (2014) Pharmacotherapy of alcohol use disorders: seventy-five years of progress. J Stud Alcohol Drugs Suppl 75(Suppl 17):79–88
16. Johnson BA (2004) Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment. CNS Drugs 18:1105–1118
17. Kenna GA (2010) Medications acting on the serotonergic system for the treatment of alcohol dependent patients. Curr Pharm Des 16:2126–2135
18. Hirani K, Sharma AN, Jain NS, Ugale RR, Chopde CT (2005) Evaluation of GABAergic neuroactive steroid 3alpha-hydroxy-5alpha-pregnane-20-one as a neurobiological substrate for the anti-anxiety effect of ethanol in rats. Psychopharmacol (Berl) 180:267–278. doi:10.1007/s00213-005-2169-7
19. Bhisikar SM, Kokare DM, Nakhate KT, Chopde CT, Subhedar NK (2009) Tolerance to ethanol sedation and withdrawal hyper-excitability is mediated via neuropeptide Y Y1 and Y5 receptors. Life Sci 85:765–772. doi:10.1016/j.lfs.2009.10.007
20. Sameer SM, Chakraborty SS, Ugale RR (2013) Agmatine attenuates acquisition but not the expression of ethanol conditioned place preference in mice: a role for imidazoline receptors. Behav Pharmacol 24:87–94. doi:10.1097/FBP.0b013e32835efc46
21. Fuller RK, Gordis E (2004) Does disulfiram have a role in alcoholism treatment today? Addiction 99:21–24
22. Lader MH (1999) Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur Neuropsychopharmacol 9(Suppl 6):S399–S405
23. Linnoila M, Stapleton JM, Lister R, Moss H, Lane E, Granger A, Eckardt MJ (1990) Effects of single doses of alprazolam and diazepam, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. Eur J Clin Pharmacol 39:21–28
24. Volpicelli JR, Volpicelli LA, O’Brien CP (1995) Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment. Alcohol 30:789–798
25. de la Monte SM, Tong M, Cohen AC, Sheedy D, Harper C, Wands JR (2008) Insulin and insulin-like growth factor resistance in alcoholic neurodegeneration. Alcohol Clin Exp Res 32:1630–1644. doi:10.1111/j.1530-0277.2008.00731.x
26. Crews FT, McElhaney R, Freund G, Ballinger WE Jr, Raizada MK (1992) Insulin-like growth factor I receptor binding in brains of Alzheimer’s and alcoholic patients. J Neurochem 58:1205–1210
27. Rojdmark S, Calissendorff J, Brismar K (2001) Alcohol ingestion decreases both diurnal and nocturnal secretion of leptin in healthy individuals. Clin Endocrinol (Oxf) 55:639–647
28. Addolorato G, Leggio L, Hillemacher T, Kraus T, Jerlhag E, Bleich S (2009) Hormones and drinking behaviour: new findings on ghrelin, insulin, leptin and volume-regulating hormones. An ESBRA Symposium report. Drug Alcohol Rev 28:160–165. doi:10.1111/j.1465-3362.2008.00023.x
29. Starkel P, De TP, Gihousse D, Duchemin J, De SC, Badaoui A (2008) Alcohol dependence is associated with reduced plasma and fundic ghrelin levels. Eur J Clin Invest 38:397–403. doi:10.1111/j.1365-2362.2008.01947.x
30. Leggio L, Zywiak WH, Fricchione SR, Edwards SM, de la Monte SM, Swift RM, Kenna GA (2014) Intravenous Ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: a preliminary investigation. Biol Psychiatry. doi:10.1016/j.biopsych.2014.03.019
31. Wurst FM, Rasmussen DD, Hillemacher T, Kraus T, Ramskogler K, Lesch O, Bayerlein K, Schanze A, Wilhelm J, Junghanns K, Schulte T, Dammann G, Pridzun L, Wiesbeck G, Kornhuber J, Bleich S (2007) Alcoholism, craving, and hormones: the role of leptin, ghrelin, prolactin, and the pro-opiomelanocortin system in modulating ethanol intake. Alcohol Clin Exp Res 31:1963–1967. doi:10.1111/j.1530-0277.2007.00531.x
32. Combettes M, Kargar C (2007) Newly approved and promising antidiabetic agents. Therapie 62:293–310. doi:10.2515/therapie:2007054
33. Kleppinger EL, Helms K (2007) The role of vildagliptin in the management of type 2 diabetes mellitus. Ann Pharmacother 41:824–832. doi:10.1345/aph.1H460
34. McIntosh CH (2008) Dipeptidyl peptidase IV inhibitors and diabetes therapy. Front Biosci 13:1753–1773
35. Miller S, St Onge EL (2006) Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother 40:1336–1343. doi:10.1345/aph.1G665
36. Pei Z (2008) From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Curr Opin Drug Discov Devel 11:512–532
37. Fujiwara K, Gotoh K, Chiba S, Masaki T, Katsuragi I, Kakuma T, Yoshimatsu H (2012) Intraportal administration of DPP-IV inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats. J Neurochem 121:66–76. doi:10.1111/j.1471-4159.2011.07563.x
38. Darsalia V, Ortsater H, Olverling A, Darlof E, Wolbert P, Nystrom T, Klein T, Sjoholm A, Patrone C (2013) The DPP-IV inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes 62:1289–1296. doi:10.2337/db12-0988
39. Darsalia V, Olverling A, Larsson M, Mansouri S, Nathanson D, Nystrom T, Klein T, Sjoholm A, Patrone C (2014) Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice. Regul Pept 190–191: 25–31. doi:10.1016/j.regpep.2014.05.001
40. D’Amico M, Di FC, Marfella R, Abbatecola AM, Ferraraccio F, Rossi F, Paolisso G (2010) Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice. Exp Gerontol 45:202–207. doi:10.1016/j.exger.2009.12.004
41. Furukawa S, Kumagi T, Miyake T, Ueda T, Niiya T, Nishino K, Murakami S, Murakami M, Matsuura B, Onji M (2012) Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature. Endocr J 59:329–333
42. Karl T, Hoffmann T, Pabst R, Von HS (2003) Extreme reduction of dipeptidyl peptidase IV activity in F344 rat substrains is associated with various behavioral differences. Physiol Behav 80:123–134
43. Karl T, Hoffmann T, Pabst R, Von HS (2003) Behavioral effects of neuropeptide Y in F344 rat substrains with a reduced dipeptidyl-peptidase IV activity. Pharmacol Biochem Behav 75:869–879
44. Dixit TS, Sharma AN, Lucot JB, Elased KM (2013) Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis. Physiol Behav 114(115):38–41. doi:10.1016/j.physbeh.2013.03.008
45. Sharma AN, Ligade S, Sharma JN, Shukla P, Elased KM, Lucot JB (2014) GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats. Metab Brain Dis Jul 15 doi:10.1007/s11011-014-9591-7